Erratum to: Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study (Expert Opinion on Investigational Drugs, (2017), 26, 4, (481-487), 10.1080/13543784.2017.1291630);Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study

Expert Opinion on Investigational Drugs

Volumn 26, Issue 4, 2017, Pages 481-487

  Espinoza Zamora, Jose Ramiro ^a   Labardini Méndez, Juan ^a   Sosa Espinoza, Alejandro ^a   López González, Celia ^a   Vieyra García, Magnolia ^a   Candelaria, Myrna ^a   Lozano Zavaleta, Valentin ^a   Toledano Cuevas, Diana Vanesa ^a   Zapata Canto, Nidia ^a   Cervera, Eduardo ^a   Dueñas González, Alfonso ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

cutaneous T cell lymphoma; Hydralazine; phase II; valproate

Indexed keywords

CHLORAMBUCIL; HYDRALAZINE; METHOTREXATE; THALIDOMIDE; VALPROATE MAGNESIUM; ANTINEOPLASTIC AGENT; VALPROIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFUSION; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MALE; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLOW RELEASE FORMULATION; TACHYCARDIA; TREATMENT DURATION; TREMOR; VOMITING; ADOLESCENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRURITUS; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDRALAZINE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PRURITUS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 85012904936     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2017.1306178     Document Type: Erratum

References (41)

1. Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome):part I. Diagnosis:clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1-16.• This is an interesting and comprehensive review of CTCL.
2. Scarisbrick JJ., New drugs in cutaneous T-cell lymphomas. Curr Opin Oncol. 2016;28:384–389.
3. Marquard L, Gjerdrum LM, Christensen IJ, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53:267–277.
4. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.•• This study led to the approval of vorinostat for CTCL by the FDA.
5. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410–5417.•• Data from this study led to the approval of romidepsin for CTCL by the FDA.
6. Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.•• Data from study led to the approval of romidepsin for CTCL by the FDA.
7. Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma:results of a phase II trial. Eur J Cancer. 2013;49:386–394.
8. Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811–819.
9. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma:promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23:3886–3896.•• This is the first study showing DNA hypermetylation at whole genome level in CTCL.
10. Dueñas-Gonzalez A, Coronel J, Cetina L, et al. Hydralazine-valproate:a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10:1433–1444.• This is a comprehensive review on the combination of hydralazine and valproate as epigenetic therapy of cancer.
11. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5:44.
12. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005;4:22.
13. Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538.
14. Mora-García MDL, Duenas-González A, Hernández-Montes J, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med. 2006;4:55.
15. Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011;39:1491–1499.
16. Arce C, Pérez-Plasencia C, González-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1:e98.
17. De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep. 2011;25:399–407.
18. Dueñas-Gonzalez A, Vega MT, Martinez-Baños D, et al. Response to hydralazine-valproate in a patient with mycosis fungoides. Case Rep Med. 2010;2010:657579.
19. Simon R. Optimal two-stage designs for phase II clinical trials.Control. Clin Trials. 1989;10:1–10.
20. Jung SH, Lee T, Kim K, et al. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004;23:561–569.
21. Livak KJ. Allelic discrimination using fluorogenic probes and the 5ʹ nuclease assay. Genet Anal. 1999;14:143–149.
22. Taja-Chayeb L, González-Fierro A, Miguez-Muñoz C, et al. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. Pharmacogenet Genomics. 2011;21:894–901.
23. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome:a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011;29:2598–2607.• Landmarking paper establishing clinical end points and diagnostic criteria for mycosis fungoides and Sezary syndrome.
24. Candelaria M, Herrera A, Labardini J, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol. 2011;90:379–387.
25. Bauman J, Shaheen M, Verschraegen CF, et al. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol. 2014;7:349–354.
26. Garcés-Eisele SJ, Cedillo-Carvallo B, Reyes-Núñez V, et al. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. J Clin Pharm Ther. 2014;39:368–375.
27. van Doorn R, Slieker RC, Boonk SE, et al. Epigenomic analysis of sézary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol. 2016;136:1876–1884.
28. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147:443–449.
29. Haider A, Steininger A, Ullmann R, et al. Inactivation of RUNX3/p46 promotes cutaneous T-cell lymphoma. J Invest Dermatol. 2016;136:2287–2296.
30. Ferrara G, Pancione M, Votino C, et al. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. Br J Dermatol. 2014;170:1266–1275.
31. Rozati S, Cheng PF, Widmer DS, et al. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clin Cancer Res. 2016;22:2020–2031.• The first preclinical study performed in a CTCL mmodel showing the synergy between DNMTi and HDACi.
32. Moreaux J, Reme T, Leonard W, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109:676–685.
33. Rempel E, Hoelting L, Waldmann T, et al. A transcriptome-based classifier to identify developmental toxicants by stem cell testing:design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015;89:1599–1618.
34. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 2006;6:2.
35. Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.• The first study showing synergy in gene expression between DNA methylation and histone deacetylase inhibitors.
36. Walton TJ, Li G, Seth R, et al. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 2008;68:210–222.
37. Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–7029.
38. Shaker S, Bernstein M, Momparler LF, et al. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2ʹ-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003;27:437–444.
39. Zhu WG, Lakshmanan RR, Beal MD, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001;61:1327–1333.
40. Nishioka C, Ikezoe T, Yang J, et al. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. Leuk Res. 2011;35:932–939.
41. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2ʹ-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int. 2008;8:16.